← Home

VFY

Healthcare & BiotechNEUTRAL

$3.790

as of 2026-09-09

5d return

-7.6%

20d return

-7.6%

60d return

+35.4%

RSI 14

39.7

vs 52w high

-18.1%

vs 52w low

+226.7%

SMA 20

Below

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike.
Loading chart…
Closest correlates
Pearson r on log returns, window: 82d
  • T3Dr=0.46, window: 82d
  • AAUr=0.31, window: 82d
  • DM1r=0.30, window: 82d
  • IOVr=0.22, window: 82d
  • RNUr=0.19, window: 82d
Announcements — last 30 days
  • 2026-09-02PSotherVitrafy enters U.S. Cell & Gene Therapy Market

    Vitrafy secures first U.S. market entry and cell & gene therapy beachhead via a 6-month, zero-revenue pilot deployment with Charter Medical—a 30-year CDMO/CGT supplier. The deal places cryopreservation hardware and software in front of established customers but carries no near-term cash flow and depends on downstream adoption to justify the investment.